Skip to content

Stockholm Acute Kidney Injury Cohort

Stockholm Prospective Acute Kidney Injury Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05111535
Acronym
SAKIS
Enrollment
1861
Registered
2021-11-08
Start date
2009-01-01
Completion date
2018-12-31
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

acute renal failure, hyperkalemia, major adverse cardiovascular event

Brief summary

Since 2009, adult patients with acute kindney injury (AKI) at the department of Nephrology, Danderyd University Hospital and Karolinska Institutet, have been included in a prospective cohort. All patients were treated and evaluated according to a detailed clinical memorandum, and data collected prospectively. By 2020, 1861 patiens have been included of which 1519 fulfill current AKI criteria (as defined by KDIGO AKI guidelines) and will be evaluated regarding the following main research questions: 1. Descriptive study on patient characteristics, changes in biomarkers and in-hospital outcome. 2. One year outcome with focus on renal and cardiovascular outcomes. 3. Long-term outcome (up to 10 years) with focus on renal and cardiovascular outcomes.

Detailed description

Acure kidney injury (AKI) remains a complex clinical challenge associated with high risk for short-term and long-term adverse events. Since 2009 patients with AKI at the department of Nephrology, Danderyd University Hospital and Karolinska Institutet, have been included in a prospective cohort. Adult patients with either s-creatinine \>130 micromol/L and previously unknown level, or 30% increase from previous known level were included; patients on dialysis were not included. All patients were treated and evaluated according to a detailed clinical memorandum, and data collected prospectively. By 2020, 1861 patiens have been included of which 1519 fulfill current AKI criteria and will be evaluated regarding the following main research questions: 1. Descriptive study on in-hospital outcome (death, renal recovery), patient characteristics, hyperkalemia and changes in biomarkers reflecting inflammation, acidosis and malnutrition. 2. One year outcome with focus on renal and cardiovascular outcomes (death, new dialysis, worsened renal function, myocardial infarction, stroke, or heart failure; MARCE). 3. Long-term outcome (up to 10 years) with focus on renal and cardiovascular outcomes (MARCE).

Interventions

None listed

Sponsors

Danderyd Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

(one of the following): * Serum creatinine (sCr) \>130 µmol/l (1.47 mg/dl) at admission with previously unknown baseline, * Increase in sCr by 30% from previous stable out-patient value.

Exclusion criteria

Ongoing dialysis treatment.

Design outcomes

Primary

MeasureTime frameDescription
Long-term outcomeFrom admission until 10 yearsDescriptive study on Major Adverse Renal or Cardiovascular Events (MARCE)
In-hospital outcomeFrom admission until discharge or death, assessed for a period of up to 3 monthsDeath
1-year outcomeFrom admission until 1 yearDescriptive study on Major Adverse Renal or Cardiovascular Events (death, new dialysis, worsened renal function, myocardial infarction, stroke, or heart failure; MARCE)

Secondary

MeasureTime frameDescription
In-hospital partial renal recoveryFrom admission until discharge or death, assessed for a period of up to 3 monthsRenal recovery by 30% at the time of discharge or death
In-hospital renal recoveryFrom admission until discharge or death, assessed for a period of up to 3 monthsRenal recovery by 50% at the time of discharge or death
In-hospital biomarkersFrom previous values or values at admission until discharge or death, assessed for a period of up to 3 monthsChanges in biomarkers with focus on potassium, malnutrition, inflammation and acidosis

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026